How much funding has Gencurix raised?

Gencurix has raised $52.1M in total funding, most recently a Series A round.

Who are Gencurix's investors?

Gencurix's investors include Korea Investment Partners, Union Ventures.

Where is Gencurix headquartered?

Gencurix is headquartered in Seoul, South Korea.

What industry is Gencurix in?

Gencurix operates in Biotech, Healthcare.

Gencurix

A new paradigm in molecular diagnostics through advanced liquid biopsy

Seoul, South Korea · $52.1M raised

Biotech

Healthcare

Headquarters: Seoul
Employees: 51–200
Business Model: B2B
Website: gencurix.com

Total Funding: $52.1M
Last Round: $24.0M Series AMar 2026
Rounds: 3

About

Gencurix (젠큐릭스) is a South Korean molecular diagnostics biotech company specializing in liquid biopsy and digital PCR-based cancer diagnostics. The company was the first Asian company to develop a prognostic diagnostic test for breast cancer and offers a portfolio of CE-IVD certified products including the Droplex cancer gene mutation detection kit, the GenesWell BCT breast cancer test, and the eDX early cancer detection system. In 2025, Gencurix signed a global supply and co-marketing agreement with Bio-Rad Laboratories — the world's largest digital PCR diagnostics company — to distribute its Droplex kits across Europe, marking a major commercial milestone for the company.

Summary

Gencurix is a Biotech company based in Seoul, South Korea. It has raised $52.1M in total across 3 rounds, most recently a $24.0M Series A round in Mar 2026. Investors include Korea Investment Partners and Union Ventures.